<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7026011/results/search/test_trace/results.xml">
  <result pre="and newborns, such as life-threatening encephalitis with sequelae, despite antiviral" exact="treatment" post="(Whitley et al., 2007; Xu et al., 2007; Dinh"/>
  <result pre="primary infections and approximately 10 days during recurrences if no" exact="treatment" post="is undertaken (Arduino and Porter, 2007). Lesion development is"/>
  <result pre="and 80–90% for HSV-1 and HSV-2 infections, respectively after primary" exact="infection" post="(Mertz et al., 1992; Benedetti et al., 1994; Cowan"/>
  <result pre="of the persons that have had clinical symptoms during primary" exact="infection" post="show frequent reactivations, which occur on average six times"/>
  <result pre="This extremely high percentage of individuals affected by symptomatic HSV" exact="infection" post="is non-negligible and undoubtedly encompasses a significant number of"/>
  <result pre="new lesions that will repeat the process of additional neuron" exact="infection" post="(Stevens and Cook, 1971; Lafferty et al., 1987; Benedetti"/>
  <result pre="1994). Given this scenario, it seems important to block neuron" exact="infection" post="by HSV-1 and HSV-2 during primary infection or to"/>
  <result pre="to block neuron infection by HSV-1 and HSV-2 during primary" exact="infection" post="or to treat neurons in such a way that"/>
  <result pre="first nucleoside analog drugs approved to control HSV-1 and HSV-2" exact="infection" post="(Hassan et al., 2015). Additionally, many plants used in"/>
  <result pre="HSV-2 At present, there are numerous antiviral drugs for the" exact="treatment" post="of HSV infections. Some commonly known anti-herpetic drugs that"/>
  <result pre="acyclovir (ACV), penciclovir, and famciclovir, which inhibit HSV-1 and HSV-2" exact="infection" post="by interfering with the viral DNA polymerase and hence,"/>
  <result pre="Hammer et al., 2018). Acyclovir Numerous antivirals approved for the" exact="treatment" post="of HSV-1 and HSV-2 infections are acyclic nucleoside and"/>
  <result pre="latent virus within host neurons and hence, does not cure" exact="infection" post="(Poole and James, 2018). Other limitations related to the"/>
  <result pre="infection (Poole and James, 2018). Other limitations related to the" exact="treatment" post="with ACV also exist. For instance, oral intake of"/>
  <result pre="significant, the clinical benefit of these antiviral drugs for the" exact="treatment" post="of herpetic lesions has been somewhat questioned (Kroon, 1990;"/>
  <result pre="will not be in time to start an effective oral" exact="treatment" post="with ACV in such a way to significantly reduce"/>
  <result pre="the herpetic lesions (Spruance et al., 1990; Spruance, 1993). Thus," exact="treatment" post="with ACV has poor benefits under these circumstances (Spruance"/>
  <result pre="et al., 2016). Valacyclovir has also been approved for the" exact="treatment" post="of HSV-1 and HSV-2 infections and clinical manifestations produced"/>
  <result pre="Foscarnet In the last decade, alternatives to ACV for herpesvirus" exact="treatment" post="have emerged and become commercially available as therapeutic drugs."/>
  <result pre="of administration (De Clercq, 2013). Ganciclovir is indicated for the" exact="treatment" post="of CMV, particularly for systemic and ocular infections in"/>
  <result pre="against HSV-1 and HSV-2 and may be used for the" exact="treatment" post="of herpetic keratitis (Smee et al., 1983; Matthews and"/>
  <result pre="oral ganciclovir, together with femtosecond laser-assisted corneal debridement in the" exact="treatment" post="of herpes simplex virus epithelial keratitis (ClinicalTrials.gov NCT03217474). Of"/>
  <result pre="2003). However, this drug has not been approved for the" exact="treatment" post="of herpes simplex viruses in humans. Yet, a clinical"/>
  <result pre="adverse effects. Unfortunately, these children showed HSV-related stomatitis during cidofovir" exact="treatment" post="and the authors suggested that the treatment with cidofovir"/>
  <result pre="stomatitis during cidofovir treatment and the authors suggested that the" exact="treatment" post="with cidofovir did not prevent HSV-1 reactivation in the"/>
  <result pre="to ACV and foscarnet (in vitro), in which case the" exact="treatment" post="with cidofovir was effective against this drug-resistant HSV-1. Another"/>
  <result pre="in a girl with lymphatic leukemia indicated that only cidofovir" exact="treatment" post="was successful at helping avoid recurrent oral stomatitis (Bryant"/>
  <result pre="reduced clinical benefits of the drugs mentioned above in the" exact="treatment" post="of skin lesions caused by herpes simplex viruses, new"/>
  <result pre="While this approach yields a statistically significant improvement in the" exact="treatment" post="of herpetic lesions, it still evidences the need for"/>
  <result pre="food industries. Currently, docosanol 10% cream is approved for the" exact="treatment" post="of HSV-1 lesions. However, the literature available on its"/>
  <result pre="another drug marketed to treat skin lesions due to HSV-2" exact="infection" post="is Viroxyn® (Quadex Pharmaceuticals), which consists of benzalkonium chloride,"/>
  <result pre="was identified as the first effective topical agent against HSV" exact="infection" post="(Chou and Hong, 2014; Wilhelmus, 2015), and was mainly"/>
  <result pre="as an ointment for treating epithelial keratitis caused by HSV-1" exact="infection" post="of the corneal epithelium (Roozbahani and Hammersmith, 2018). However,"/>
  <result pre="a synthetic pyrimidine nucleoside that is frequently used for the" exact="treatment" post="of herpetic keratitis as a topical formulation. This drug"/>
  <result pre="FDA in 1980 for its use as a 1% solution" exact="treatment" post="for HSV-related keratitis and is at present one of"/>
  <result pre="HSV-1 and at least as effective as acyclovir in the" exact="treatment" post="of HSV-1 infection (Chou and Hong, 2014). Currently, is"/>
  <result pre="least as effective as acyclovir in the treatment of HSV-1" exact="infection" post="(Chou and Hong, 2014). Currently, is mainly used in"/>
  <result pre="Hong, 2014). Currently, is mainly used in different countries for" exact="treatment" post="of VZV infections (De Clercq, 2019). Compounds Against HSVs"/>
  <result pre="phase for immunocompromised subjects with acyclovir-resistant mucocutaneous HSV-1 or HSV-2" exact="infection" post="(ClinicalTrials.gov Identifier: NCT03073967). Amenamevir is an oxadiazolephenyl derivate that"/>
  <result pre="is currently being assessed in a clinical study for the" exact="treatment" post="of patients with Kaposi’s sarcoma, as well as its"/>
  <result pre="antiviral activity against HSV was observed in early stages of" exact="infection" post="affecting the attachment of HSV. Additionally, it was shown"/>
  <result pre="protein which is normally found in the nucleus. After the" exact="treatment" post="with the alga extract, VP5 was mainly found in"/>
  <result pre="Morus alba (White Mulberry) Inhibition of early stages of viral" exact="infection" post="HSV-1 and HSV-2 ✓ Unknown or not reported Kuwanon"/>
  <result pre="which has been shown to be capable of inhibiting HSV" exact="infection" post="in a murine model of HSV-2 infection (Figure 1)"/>
  <result pre="of inhibiting HSV infection in a murine model of HSV-2" exact="infection" post="(Figure 1) (Nixon et al., 2013). The mechanism of"/>
  <result pre="consists on its binding to mannose N-glycosylations that blocks the" exact="infection" post="process of HSV-2 and inhibits cell-to-cell spread of the"/>
  <result pre="of infection. The study showed a strong reduction in HSV-2" exact="infection" post="when applied together as a prophylactic, namely between 10"/>
  <result pre="prophylactic, namely between 10 min and 1 h prior to" exact="infection" post="(Levendosky et al., 2015). A more recent article reported"/>
  <result pre="skin lesions compared to controls when administrated 4 h before" exact="infection" post="and then three times per day for 6–10 days."/>
  <result pre="effect of fucoidan was tested in another study against corneal" exact="infection" post="with HSV-1, a reduction in herpetic lesions was found"/>
  <result pre="HSV-2 to Vero cells, inhibiting the early phase of HSV-2" exact="infection" post="(Alboofetileh et al., 2019). Table 2 summarizes the antiviral"/>
  <result pre="penetration assays suggest an antiviral effect at early stages of" exact="infection" post="(Sun et al., 2019). Fungus-Derived Compounds With Antiviral Activity"/>
  <result pre="which was suggested to have virucidal activity when in direct" exact="contact" post="with HSV-1 and HSV-2 (Figure 1) (Rowley et al.,"/>
  <result pre="extract from Inonotus obliquus (AEIO) was shown to inhibit HSV-1" exact="infection" post="in Vero cells (Pradeep et al., 2019). the antiviral"/>
  <result pre="(Pradeep et al., 2019). Interestingly, fungus proteins that inhibit HSV" exact="infection" post="have also been identified. Two proteins that bind polysaccharides"/>
  <result pre="reduce the severity of HSV-2 disease in a murine genital" exact="infection" post="model with one single application (Cardozo et al., 2013)."/>
  <result pre="identified antiviral activity against HSV-1, which was effective after the" exact="infection" post="of Vero cells (Figure 1) (Venturi et al., 2015)."/>
  <result pre="of E. camaldulensis were shown to inhibit HSV-1 and HSV-2" exact="infection" post="when the extracts were added to Vero cells during-"/>
  <result pre="effect acting pre-treatment (virucidal), thus inhibiting virus entry and subsequent" exact="infection" post="processes, while the antiviral effect against HSV-1 was only"/>
  <result pre="extract was incubated with the virus previous to the cell" exact="infection" post="(Okba et al., 2017). In addition, twelve compounds isolated"/>
  <result pre="has antiviral activity over HSV at multiple steps of the" exact="infection" post="process, inhibiting cellular adsorption and penetration, as well as"/>
  <result pre="extracts from Houttuynia cordata, a Chinese herbal medicine, blocks HSV-2" exact="infection" post="by inhibiting NF-κB activation, a host transcription factor that"/>
  <result pre="that has been reported to be required for effective HSV" exact="infection" post="(Amici et al., 2006). In order to identify the"/>
  <result pre="is added to the inoculum for 1 h before viral" exact="infection" post="or immediately after viral infection (Rattanathongkom et al., 2009)."/>
  <result pre="for 1 h before viral infection or immediately after viral" exact="infection" post="(Rattanathongkom et al., 2009). The authors suggested that the"/>
  <result pre="2009). Moreover, Chikusetsusaponin IV showed antiviral activity against HSV-2 genital" exact="infection" post="in mice when administrated three times per day three"/>
  <result pre="mice when administrated three times per day three days before" exact="infection" post="and up to 7 days after infection (Rattanathongkom et"/>
  <result pre="three days before infection and up to 7 days after" exact="infection" post="(Rattanathongkom et al., 2009). Finally, Meliacine (MA) a glycopeptide"/>
  <result pre="showed favorable results against HSV-2 in a mouse model of" exact="infection" post="when applied topically immediately after infection with HSV-2 (Petrera"/>
  <result pre="a mouse model of infection when applied topically immediately after" exact="infection" post="with HSV-2 (Petrera and Coto, 2009). Table 2 summarizes"/>
  <result pre="such a way to validate potential new drugs for the" exact="treatment" post="of herpes simplex virus manifestations. Regarding herpes labialis, a"/>
  <result pre="to the best of our knowledge. Another study involving the" exact="treatment" post="of herpes labialis lesions was performed with Huanglian-Jiedu Decoction,"/>
  <result pre="forward into clinical studies without the need of non-clinical pharmacological/toxicological" exact="testing" post="if they have already been proven to have a"/>
  <result pre="BenzekriR.BouslamaL.PapettiA.HammamiM.SmaouiA.LimamF. (2018). Anti HSV-2 activity of Peganum harmala (L.) and" exact="isolation" post="of the active compound.Microb. Pathog.114291–298. 10.1016/j.micpath.2017.12.01729223449 BlotN.SchneiderP.YoungP.JanvresseC.DehesdinD.TronP.et al. (2000)."/>
  <result pre="(2000). Treatment of an acyclovir and foscarnet-resistant herpes simplex virus" exact="infection" post="with cidofovir in a child after an unrelated bone"/>
  <result pre="compounds isolated from Eucalyptus globulus labill.Viruses10:360. 10.3390/v1007036029986399 BryantP.SasadeuszJ.CarapetisJ.WatersK.CurtisN. (2001). Successful" exact="treatment" post="of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in"/>
  <result pre="infection.PLoS Pathog.2:e69. 10.1371/journal.ppat.002006916839203 BuhlesW. C.MastreB. J.TinkerA. J.StrandV.KoretzS. H. (1988). Ganciclovir" exact="treatment" post="of life-or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised"/>
  <result pre="al. (2016). Efficacy and safety of nucleoside antiviral drugs for" exact="treatment" post="of recurrent herpes labialis: a systematic review and meta-analysis.J."/>
  <result pre="Med.46561–568. 10.1111/jop.1253427935123 ChenX.QiaoH.LiuT.YangZ.XuL.XuY.et al. (2012). Inhibition of herpes simplex virus" exact="infection" post="by oligomeric stilbenoids through ROS generation.Antiviral. Res.9530–36. 10.1016/j.antiviral.2012.05.00122584350 ChenX.WangZ.YangZ.WangJ.XuY.TanR.et"/>
  <result pre="generation.Antiviral. Res.9530–36. 10.1016/j.antiviral.2012.05.00122584350 ChenX.WangZ.YangZ.WangJ.XuY.TanR.et al. (2011). Houttuynia cordata blocks HSV" exact="infection" post="through inhibition of NF-κB activation.Antiviral. Res.92341–345. 10.1016/j.antiviral.2011.09.00521951655 ChenY. C.ShengJ.TrangP.LiuF."/>
  <result pre="ChouT. Y.HongB. Y. (2014). Ganciclovir ophthalmic gel 0.15% for the" exact="treatment" post="of acute herpetic keratitis: background, effectiveness, tolerability, safety, and"/>
  <result pre="placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for" exact="treatment" post="of UV radiation-induced herpes labialis.Antimicrob. Agents Chemother.461870–1874. 10.1128/aac.46.6.1870-1874.200212019102 FaithS."/>
  <result pre="R.GodfreyN. J.GodfreyJ. C.RileyD. (2001). A randomized clinical trial on the" exact="treatment" post="of oral herpes with topical zinc oxide/glycine.Altern. Ther. Heal."/>
  <result pre="the efficacy of topical acyclovir, penciclovir, and docosanol for the" exact="treatment" post="of herpes simplex labialis.EMJ Dermatol.6118–123. HandelS.KlinglerE. J.WashburnK.BlankS.SchillingerJ. A. (2011)."/>
  <result pre="Ther.141104226–239. KawashimaM.NemotoO.HondaM.WatanabeD.NakayamaJ.ImafukuS.et al. (2017). Amenamevir, a novel helicase–primase inhibitor, for" exact="treatment" post="of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3"/>
  <result pre="al. (2002). New helicase-primase inhibitors as drug candidates for the" exact="treatment" post="of herpes simplex disease.Nat. Med.8392–398. 10.1038/nm0402-39211927946 KroonS. (1990). Genital"/>
  <result pre="in combination with acyclovir against herpes simplex virus type 1" exact="infection" post="in vitro and in vivo.Antivir. Res.2719–37. 10.1016/0166-3542(94)00076-k7486956 KwantA.RosenthalK. L."/>
  <result pre="and genital herpes simplex virus infection. Influence of site of" exact="infection" post="and viral type.N. Engl. J. Med.3161444–1449. 10.1056/nejm1987060431623043033506 LeaA. P.BrysonH."/>
  <result pre="(2007). A meta-analysis to assess the efficacy of oral antiviral" exact="treatment" post="to prevent genital herpes outbreaks.J. Am. Acad. Dermatol.57238–246. 10.1016/j.jaad.2007.02.00817416440"/>
  <result pre="L.FletcherC. V. (2000). A risk-benefit evaluation of aciclovir for the" exact="treatment" post="and prophylaxis of herpes simplex virus infections.Drug Saf.23131–142. 10.2165/00002018-200023020-0000410945375"/>
  <result pre="Thai medicinal plant extracts against herpes simplex virus type 1" exact="infection" post="in vitro and in vivo.Antiviral. Res.60175–180. 10.1016/s0166-3542(03)00152-914638393 LolisM. S.GonzalezL.CohenP."/>
  <result pre="LookerK. J.GarnettG. P.SchmidG. P. (2008). An estimate of the global" exact="prevalence" post="and incidence of herpes simplex virus type 2 infection.Bull."/>
  <result pre="J. Biol. Macromol.102605–612. 10.1016/j.ijbiomac.2017.04.04328431944 LuberA. D.FlahertyJ. F. (1996). Famciclovir for" exact="treatment" post="of herpesvirus infections.Ann. Pharmacother.30978–985. 10.1177/1060028096030009138876860 MaF.ShenW.ZhangX.LiM.WangY.ZouY.et al. (2016). Anti-HSV"/>
  <result pre="C.LewisJ. S.LitchfieldB.PettusK. S.et al. (1998). Etiology of genital ulcers and" exact="prevalence" post="of human immunodeficiency virus coinfection in 10 US cities."/>
  <result pre="F.NotkinsA. L.StrausS. E. (1987). Reactivation of latent herpes simplex virus" exact="infection" post="by ultraviolet light: a human model.J. Am. Acad. Dermatol.17473–478."/>
  <result pre="herpes simplex virus isolates from patients using penciclovir cream for" exact="treatment" post="of recurrent herpes labialis.Antimicrob. Agents Chemother.462848–2853. 10.1128/aac.46.9.2848-2853.200212183237 SariskyR. T.BaconT."/>
  <result pre="H.BoonR. J.DuffyK. E.EsserK. M.LearyJ.et al. (2003). Profiling penciclovir susceptibility and" exact="prevalence" post="of resistance of herpes simplex virus isolates across eleven"/>
  <result pre="K.HarderB. C.SchlichtenbredeF. C.JarczokM. N.TesarzJ. (2016). Valacyclovir versus acyclovir for the" exact="treatment" post="of herpes zoster ophthalmicus in immunocompetent patients.Cochrane Database Syst."/>
  <result pre="SempriniA.SingerJ.BraithwaiteI.ShorttN.ThayabaranD.McConnellM.et al. (2019). Kanuka honey versus aciclovir for the topical" exact="treatment" post="of herpes simplex labialis: a randomised controlled trial.BMJ Open9:e026201."/>
  <result pre="nucleoside 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine.Antimicrob. Agents Chemother.23676–682. 10.1128/aac.23.5.6766307132 SmithJ. S.RobinsonN. J. (2002). Age-specific" exact="prevalence" post="of infection with herpes simplex virus types 2 and"/>
  <result pre="Agents Chemother.23676–682. 10.1128/aac.23.5.6766307132 SmithJ. S.RobinsonN. J. (2002). Age-specific prevalence of" exact="infection" post="with herpes simplex virus types 2 and 1: a"/>
  <result pre="(2005). Survey of acyclovir-resistant herpes simplex virus in the Netherlands:" exact="prevalence" post="and characterization.J. Clin. Virol.327–18. 10.1016/j.jcv.2004.04.00215572000 SuazoP. A.TognarelliE. I.KalergisA. M.GonzálezP."/>
  <result pre="ThinR. N.NabarroJ. M.ParkerJ. D.FiddianA. P. (1983). Topical acyclovir in the" exact="treatment" post="of initial genital herpes.Sex Transm. Infect.59116–119. 10.1136/sti.59.2.1166338997 ThomfordN. E.SenthebaneD."/>
  <result pre="Pharmacovigilance Systems.Geneva: World Health Organisation, 82. WilhelmusK. R. (2015). Antiviral" exact="treatment" post="and other therapeutic interventions for herpes simplex virus epithelial"/>
 </snippets>
</snippetsTree>
